Indoleamine and the phenethylamine hallucinogens: Mechanisms of psychotomimetic action

Drug and Alcohol Dependence

Volumn 51, Issue 1-2, 1998, Pages 189-198

  Marek, Gerard J ^a   Aghajanian, George K ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERGOLINE DERIVATIVE; INDOLEAMINE; LYSERGIDE; PSYCHEDELIC AGENT; SEROTONIN RECEPTOR;

CENTRAL NERVOUS SYSTEM; DRUG ABUSE; FACIAL NERVE NUCLEUS; HALLUCINATION; HUMAN; INTERNEURON; LOCUS CERULEUS; MOTOR ACTIVITY; NEOCORTEX; NERVE PROJECTION; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; REVIEW; SCHIZOPHRENIA; SYNAPTIC POTENTIAL;

EID: 0032104636     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0376-8716(98)00076-3     Document Type: Article

References (79)

1. Abraham, H.D., 1983a. Visual phenomenology of the LSD flashback. Arch. Gen. Psychiatry 40, 884-889.
2. Abraham, H.D., 1983b. L-5-hydroxytryptophan for LSD-induced psychosis. Am. J. Psychiatry 140, 456-458.
3. 1 receptor subtype coupled to the inhibition of adenylate cyclase. Proc. Natl. Acad. Sci. U.S.A. 90, 408-412.
4. Aghajanian, G.K., 1980. Mescaline and LSD facilitate the activation of locus coeruleus neurons by peripheral stimuli. Brain Res. 186, 492-498.
5. Aghajanian, G.K., Bing, O.H.L., 1964. Persistence of lysergic acid diethylamide in the plasma of human subjects. Clin. Pharmacol. Ther. 5, 611-614.
6. Aghajanian, G.K., Marek, G.J., 1997. Serotonin induces excitatory postsynaptic potentials in apical dendrites of neocortical pyramidal cells. Neuropharmacology 36, 589-599.
7. 2A receptors selectively enhance asynchronous excitatory transmission in layer V cortical pyramidal cells, Soc. Neurosci. Abstr. 24.
8. Aghajanian, G.K., Foote, W.E., Sheard, M.H., 1968. Lysergic acid diethylamide: sensitive neuronal units in the midbrain raphe. Science 161, 706-708.
9. 1A receptors mediate opposing responses on membrane excitability in rat association cortex. Neuroscience 40, 399-412.
10. 2 receptors and serotonergic axons in rat neocortex. Brain Res. 453, 315-328.
11. Bowers, M.B.J., 1977. Psychoses precipitated by psychotomimetic drugs. Arch. Gen. Psychiatry 34, 832-835.
12. Cleghorn, J.M., Garnett, E.S., Nahmias, C., et al., 1989. Increased frontal and reduced parietal glucose metabolism in acute untreated schizophrenics. Psychiatry Res. 28, 119-133.
13. Duxon, M.S., Flanigan, T.P., Reavley, A.C., Baxter, G.S., Blackburn, T.P., Fone, K.C.F., 1997. Evidence for expression of the 5-hydroxytryptamine-2B receptor protein in the rat central nervous system. Neuroscience 76, 323-329.
14. Ebmeier, K.P., Blackwood, D.H.R., Murray, C., et al., 1993. Single-photon emission computed tomography with [99m]Tc-Exametazime in unmedicated schizophrenic patients. Biol. Psychiatry 33, 487-495.
15. Erlander, M.G., Lovenberg, T.W., Baron, B.M., et al., 1993. Two members of a distinct subfamily of 5-hydroxytryptamine receptors differentially expressed in rat brain. Proc. Natl. Acad. Sci. U.S.A. 90, 3452-3456.
16. Gaddum, J.H., 1953. Antagonism between lysergic acid diethylamide and 5-hydroxytryptamine. J. Physiol. (London) 121, 15P.
17. h: intracellular studies in rat facial motoneurons. Synapse 13, 123-134.
18. Gellman, R.L., Aghajanian, G.K., 1993. Pyramidal cells in piriform cortex receive a convergence of inputs from monoamine activated GABAergic interneurons. Brain Res. 600, 63-73.
19. 4 receptor: Molecular cloning and pharmacological characterization of two splice variants. EMJO J. 14, 2806-2815.
20. Glass, G.S., Bowers, M.B.J., 1970. Chronic psychosis associated with long-term psychotomimetic drug abuse. Arch. Gen. Psychiatry 23, 97-103.
21. 2 agonists or antagonists? Neuropsychopharmacology 3, 509-517.
22. 2 involvement in the mechanism of action of hallucinogenic agents. Life Sci. 35, 2502-2511.
23. Goda, Y., Stevens, C.F., 1994. Two components of transmitter release at a central synapse. Proc. Natl. Acad. Sci. U.S.A. 91, 12942-12946.
24. Haigler, H.J., Aghajanian, G.K., 1973. Mescaline and LSD: direct and indirect effects on serotonin-containing neurons in brain. Eur. J. Pharmacol. 21, 53-60.
25. Hawks, R.L., Chiang, C.N., 1986. Urine Testing for Drugs of Abuse. National Institute on Drug Abuse, Research Monograph 73. U.S. Department of Health and Human Services, Rockville, MD.
26. Hermle, L., Funfgeld, M., Oepen, G., et al., 1992. Mescaline-induced psychopathological, neuropsychological, and neurometabolic effects in normal subjects: Experimental psychosis as a tool for psychiatric research. Biol. Psychiatry 32, 976-991.
27. 1 recognition sites. J. Recept. Res. 8, 59-81.
28. Hoyer, D., Pazos, A., Probst, A., Palacios, J.M., 1986. Serotonin receptors in the human brain. II. Characterization and autoradiographic localization of 5-HT1C and 5-HT2 recognition sites. Brain Res. 376, 97-107.
29. Hoyer, D., Clarke, D.E., Fozard, J.R., et al., 1994. VII. International Union of Pharmacology Classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol. Rev. 46, 157-203.
30. Hubel, D.H., Wiesel, T.N., 1977. Functional architecture of macaque monkey visual cortex (Ferrier lecture). Proc. R. Soc. London B 198, 1-59.
31. Jakab, R.L., Goldman-Rakic, P.S., 1998. 5-HT2A serotonin receptors in the primate cerebral cortex: Possible site of action of hallucinogens in pyramidal cell apical dendrites. Proc. Natl. Acad. Sci. U.S.A. 95, 735-740.
32. Kaplan, R.D., Szechtman, H., Franco, S., et al., 1993. Three clinical syndromes of schizophrenia in untreated subjects: relation to glucose activity measured by positron emission tomography (PET). Schizophr. Res. 11, 47-54.
33. Katz, B., Miledi, R., 1965. The effect of calcium on acetylcholine release from motor nerve terminals. Proc. R. Soc. London B 161, 483-495.
34. Krystal, J.H., Karper, L.P., Seibyl, J.P., et al., 1994. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive and neuroendocrine responses. Arch. Gen. Psychiatry 51, 199-214.
35. Lahti, A.C., Koffel, B., LaPorte, D., Tamminga, C.A., 1995. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 13, 9-19.
36. 2+ sensors for the fast and slow components of neurotransmitter release. J. Biol. Chem. 270, 24898-24902.
37. 3H]MDL 100,907. Naunyn-Schmiedeberg's Arch. Pharmacol. 356, 446-454.
38. 1E-like rat and human 5-hydroxytryptamine receptor genes. Proc. Natl. Acad. Sci. U.S.A. 90, 2184-2188.
39. 7) implicated in the regulation of mammalian circadian rhythms. Neuron 11, 449-458.
40. Maj, J., Palider, W., Baran, L., 1976. The effects of serotonergic and antiserotonergic drugs on the flexor reflex of spinal rat: a proposed model to evaluate the action on the central serotonin receptor. J. Neural Transm. 38, 131-147.
41. Maj, J., Palider, W., Rawlow, A., 1977. The influence of mescaline on the flexor reflex of the hind limb of the spinal rat. J. Pharm. Pharmacol. 29, 177-178.
42. 2A receptor antagonist. Eur. J. Pharmacol. 259, 137-141.
43. 2A receptors on neurons in the rat piriform cortex. J. Pharmacol. Exp. Ther. 278, 1373-1382.
44. Marek, G.J., Aghajanian, G.K., 1997. Serotonin-2A receptor induced EPSCs in apical dendrites of layer V pyramidal cells of prefrontal cortex: block by μ-opiate receptor agonists. Soc. Neurosci. Abstr. 23, 974.
45. 5B receptors define a new family of serotonin receptors: Cloning, functional expression, and chromosomal localization. Mol. Pharmacol. 43, 313-319.
46. McCall, R.B., Aghajanian, G.K., 1979. Serotonergic facilitation of facial motoneuron excitation. Brain Res. 169, 11-27.
47. McCall, R.B., Aghajanian, G.K., 1980. Pharmacological characterization of serotonin receptors in the facial motor nucleus: a microiontophoretic study. Eur. J. Pharmacol. 65, 175-183.
48. McCormick, D.A., Pape, H.C., 1990. Properties of a hyperpolarization-activated cation current and its role in rhythmic oscillation in thalamic relay neurones. J. Physiol. Lond. 431, 291-318.
49. Monsma, F.J., Shen, Y., Ward, R.P., Hamblin, M.W., Sibley, D.R., 1993. Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol. Pharmacol. 43, 320-327.
50. Parellada, E., Catafau, A.M., Bernardo, M., Lomena, F., Gonzalez-Monclus, E., Setoain, J., 1994. Prefrontal dysfunction in young acute neuroleptic-naive schizophrenic patients: a resting and activation SPECT study. Psychiatry Res.: Neuroimaging 55, 131-139.
51. Pazos, A., Palacios, J.M., 1985. Quantitative autoradiographic mapping of serotonin receptors in the rat brain. I. Serotonin-1 receptors. Brain Res. 346, 205-230.
52. 3 recognition sites in rat cortical membranes. Eur. J. Pharmacol. 148, 297-299.
53. 2 receptor-mediated phosphatidylinositol turnover by D-lysergic acid diethylamide. J. Pharmacol. Exp. Ther. 247, 918-925.
54. Pierce, P.A., Peroutka, S.J., 1989. Hallucinogenic drug interactions with neurotransmitter receptor binding sites in human cortex. Psychopharmacology 97, 118-122.
55. Pierce, P.A., Peroutka, S.J., 1990. D-Lysergic acid diethylamide differentially affects the dual actions of 5-hydroxytryptamine on cortical neurons. Neuropharmacology 29, 705-712.
56. 2C receptors. Mol. Brain Res. 23, 163-178.
57. Powell, T.P.S., Mountcastle, V.B., 1959. Some aspects of the functional organization of the neocortex of the postcentral gyrus of the monkey: A correlation of findings obtained in a single unit analysis with cytoarchitecture. Bull. Johns Hopkins Hosp. 105, 133-162.
58. 2 antagonists. Brain Res. 385, 395-400.
59. 2 binding affinity. Neuropsychopharmacology 1, 101-107.
60. Rasmussen, K., Aghajanian, G.K., 1990. Serotonin excitation of facial motoneurons: receptor subtype characterization. Synapse 5, 324-332.
61. 7) activating cAMP formation. Proc. Natl. Acad. Sci. U.S.A. 90, 8547-8551.
62. Sanders-Bush, E., Burris, K.D., Knoth, K., 1988. Lysergic acid diethylamide and 2,5-dimethoxy-4-methylamphetamine are partial agonists at serotonin receptors linked to phosphoinositide hydrolysis. J. Pharmacol. Exp. Ther. 246, 924-928.
63. Shaw, E., Woolley, D.W., 1956. Some serotoninlike activities of lysergic acid diethylamide. Science 124, 121-122.
64. 2-activated interneuron. Brain Res. 506, 62-69.
65. 2 receptors in interneurons. Synapse 9, 208-218.
66. 2-receptor mediation. Eur. J. Pharmacol. 176, 135-142.
67. 1B agonists. Synapse 1, 3-9.
68. Tanaka, E., North, R.A., 1993. Actions of 5-hydroxytryptamine on neurons of the rat cingulate cortex. J. Neurophysiol. 69, 1749-1757.
69. 2 receptor as a site of action for LSD and phenethylamine hallucinogens. Psychopharmacology 94, 213-216.
70. Vaidya, V.A., Marek, G.J., Aghajanian, G.K., Duman, R.S., 1997. 5-HT2A receptor mediated regulation of brain-derived neurotrophic factor mRNA in the hippocampus and the neocortex. J. Neurosci. 17, 2785-2795.
71. VanderMaelen, C.P., Aghajanian, G.K., 1982. Serotonin-induced depolarization of rat facial motoneurons in vivo: comparison with amino acid transmitters. Brain Res. 239, 139-152.
72. Vardy, M.M., Kay, S.R., 1983. LSD psychosis or LSD-induced schizophrenia. Arch. Gen. Psychiatry 40, 877-883.
73. Vollenweider, F.X., Leenders, K.L., Scharfetter, C., et al., 1997a. Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using emission tomography (PET) and [18F] fluorodeoxyglucose (FDG). Eur. Neuropsychopharmacol. 7, 9-24.
74. Vollenweider, F.X., Leenders, K.L., Scharfetter, C., Maguire, P., Stadelmann, O., Angst, J., 1997b. Positron emission tomography and fluorodeoxyglucose studies of metabolic hyerfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology 16, 357-372.
75. Willins, D.L., Deutch, A.Y., Roth, B.L., 1997. Serotonin 5-HT2A receptors are expressed on pyramidal cells and interneurons in the rat cortex. Synapse 27, 79-82.
76. Woodward, D.J., Moises, H.C., Waterhouse, B.D., Hoffer, B.J., Freedman, R., 1979. Modulatory actions of norepinephrine in the central nervous system. Fed. Proc. 38, 2109-2116.
77. Woolley, D.W., Shaw, E., 1954. A biochemical and pharmacological suggestion about certain mental disorders. Proc. Natl. Acad. Sci. U.S.A. 40, 228-231.
78. 2 receptor subtype mRNAs in rat brain. J. Compar. Neurol. 351, 357-373.
79. 1E receptor. Mol. Pharmacol. 42, 180-185.